Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
CRM Triad Follow-up
Have you made changes to your practice behaviors after participating in this presentation?
[ Required ]
YES
NO
Have you seen improvements to patient outcomes as a result of your changes?
[ Required ]
Select...
YES
NO
Would you tell us about those improvements?
Do you do the following less, the same as, or more than before the presentation?
Screen patients for T2D, HF, and/or CKD in accordance with clinical guidelines to make a diagnosis in the disease course
[ Required ]
Select...
More than
Same as
Less than
Integrate therapeutic agents for CRM conditions based on evidence-based guideline recommendations into treatment regimens
[ Required ]
Select...
More than
Same as
Less than
Involve members of the multidisciplinary team in the care of patients with T2D, HF, and/or CKD
[ Required ]
Select...
More than
Same as
Less than
Which of the following is true about screening for CKD in patients with diabetes?
[ Required ]
Cystatin C and creatine testing are preferred for initial CKD screening
Only checking eGFR is recommended since it independently predicts CVD mortality
Only checking UACR is recommended since it independently predicts CVD mortality
Checking eGFR and UACR is recommended since both independently predict CVD mortality
Certain agents from which of the following drug classes have FDA approval for indications of T2D, HF(regardless of injection fraction), and CKD(with or without diabetes)?
[ Required ]
ACE inhibitors
SGLT2 inhibitors
GLP-1 receptor agonists
Nonsteroidal MRAs
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
To be entered for our Amazon gift card give-away, please enter your email address below.
[ Invalid e-mail address ]
Submit